# Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

> **NCT01285518** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 84 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01285518
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01285518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01285518, "Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01285518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*